Genmab — December 2022

[E_L]

Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma https://www.janssen.com/janssen-presents-new-data-talquetamab-first-class-gprc5dxcd3-bispecific-antibody-suggesting-durable

[E_L]

It's a while ago this was written 'Assuming epco gets approved, and 1 biontech duobody, then for these first 9 Genmab approved antibodies, 8 of them will be blockbusters, Kesimpta will be multiple blockbuster, Teclistamab, Talquetamab, Tepezza now are prognosed for >$4bn and Dara and Rybrevant >$5bn. That is just unheard of for a biotech.' but seems fully on track... maybe Mim8 will be #9 though, as GB suggested or even Inclacumab...

[E_L]

Ash 2022 – talquetamab heads to the regulators https://www.evaluate.com/vantage/articles/events/conferences-trial-results/ash-2022-talquetamab-heads-regulators

[E_L]

PET scan for Richters / epco https://twitter.com/asernapareja/status/1601716206050115584/photo/1

[Bulder]

Seems like a little concern over the fatal infections in the tec-dara-len combo. One covid and one sepsis. Hope this will be discussed on R&D Day.

[Bulder]

https://www.youtube.com/watch?v=8yirKYro2cw talquetamab

[ProinvestorNEWS]

Just a moment...

(www.proinvestor.com)

[GeorgeBest]

@Bulder. Jan will probably say it is a Janssen product, and refer the analyst to them.

[Bulder]

Also talq had 2 deaths due to covid. Maybe this problem will be solved when covid is over.

[Bulder]

GB: I think they should discuss the general issue with risk of infections and bispecifics.

[E_L]

at the same time, according to Dr Chari: “If you measure Covid antibodies, patients on [talquetamab] are producing antibodies. That’s a really different signal than what we’ve seen before.”

[Bulder]

Ye s, but as he says, it is tragic to loose a cr- patient to covid. I would like to hear if they can come up with something to avoid infections.

[Bulder]

Does anybody know when hex38 will be presented.

[E_L]

tonight https://ash.confex.com/ash/2022/webprogram/Paper159116.html

[E_L]

but it is a poster, so you have to hope someone will post something on twitter, we'll probably have to wait for the R&D

[E_L]

rest of the schedule by the way: https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-64th-annual

[ProinvestorNEWS]

ASH tråd. Fyld gerne på: https://www.proinvestor.com/boards/108608/

[Solsen]

Rafineret teknologi viser gode resultater. Dejligt med de mange fremskridt i cancerbehandling https://www.bbc.com/news/health-63859184

[Bulder]

Ham her har visse indvendinger imod talq-studiet: https://www.youtube.com/watch?v=PAvLpjVstOk

[Helge_LarsenPI-redaktør]

Den første del af kritikken er svært for lægmand at vurdere. Håber at nogen af vore eksperter kan byde ind. Det med det uetiske med den homøopatiske dosering i lavdosisgruppen er til gengæld nemt for de fleste at forstå og være enig i. Det er jeg i hvert fald.